An array of protein-based therapies is being launched in the market for an increasing range of application treatments. These products typically present as difficult to inspect, they characterize as dense emulsions and suspensions, lyophilized or unstable complex biotech drugs (mAbs) to quote a few. Difficult-to-inspect products (DIP) call for new challenges, requiring vendors operating in the pharma visual inspection to master inspection technologies to ensure product integrity, for patients’ safety. Contrary to current belief, Automatic Visual Inspection for these drugs can be successfully implemented and support pharma companies to reach their productivity goals. This webinar will provide a platform to illustrate the latest techniques available today and how Stevanato Group is addressing these challenges. Through best practices we will cover results obtained in the inspection of a comprehensive range of difficult-to-inspect products. The discussion will also address the emergence of Artificial Intelligence and the results it can deliver.